He­palys to de­vel­op In­ven­ti­va’s NASH treat­ment; Ever­est li­cens­es Kezar’s au­toim­mune drug

He­palys Phar­ma said Thurs­day it will de­vel­op and com­mer­cial­ize In­ven­ti­va’s non­al­co­holic steato­hep­ati­tis (NASH) treat­ment in Japan and South Ko­rea, pay­ing $10 mil­lion up­front and up to $231 mil­lion in mile­stones as well as roy­al­ties.

The drug, lan­i­fi­bra­nor, is cur­rent­ly in a Phase III tri­al.

Ever­est Med­i­cines li­cens­es Kezar’s au­toim­mune drug in Chi­na and oth­er re­gions in Asia

Chi­na-based Ever­est Med­i­cines is li­cens­ing Kezar Life Sci­ences’ ze­tomip­zomib, which is be­ing test­ed as a treat­ment for lu­pus nephri­tis, in Greater Chi­na, South Ko­rea, and some South­east Asian coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER